• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

分离和功能分析针对葡萄球菌超抗原样蛋白的噬菌体展示抗体片段。

Isolation and functional analysis of phage-displayed antibody fragments targeting the staphylococcal superantigen-like proteins.

机构信息

Faculty of Sciences and Engineering, Pharmaceutical Sciences Laboratory (Pharmacy) & Structural Bioinformatics Laboratory (Biochemistry) Turku, Åbo Akademi University, Turku, Finland.

Department of Life Technologies, University of Turku, Turku, Finland.

出版信息

Microbiologyopen. 2023 Aug;12(4):e1371. doi: 10.1002/mbo3.1371.

DOI:10.1002/mbo3.1371
PMID:37642487
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10350561/
Abstract

Staphylococcus aureus produces numerous virulence factors that manipulate the immune system, helping the bacteria avoid phagocytosis. In this study, we are investigating three immune evasion molecules called the staphylococcal superantigen-like proteins 1, 5, and 10 (SSL1, SSL5, and SSL10). All three SSLs inhibit vital host immune processes and contribute to S. aureus immune evasion. This study aimed to identify single-chain variable fragment (scFvs) antibodies from synthetic antibody phage libraries, which can recognize either of the three SSLs and could block the interaction between the SSLs and their respective human targets. The antibodies were isolated after three rounds of panning against SSL1, SSL5, and SSL10, and their ability to bind to the SSLs was studied using a time-resolved fluorescence-based immunoassay. We successfully obtained altogether 44 unique clones displaying binding activity to either SSL1, SSL5, or SSL10. The capability of the SSL-recognizing scFvs to inhibit the SSLs' function was tested in an MMP9 enzymatic activity assay, a P-selectin glycoprotein ligand 1 competitive binding assay, and an IgG1-mediated phagocytosis assay. We could show that one scFv was able to inhibit SSL1 and maintain MMP9 activity in a concentration-dependent manner. Finally, the structure of this inhibiting scFv was modeled and used to create putative scFv-SSL1-complex models by protein-protein docking. The complex models were subjected to a 100-ns molecular dynamics simulation to assess the possible binding mode of the antibody.

摘要

金黄色葡萄球菌产生许多毒力因子,这些因子可以操纵免疫系统,帮助细菌避免吞噬作用。在这项研究中,我们正在研究三种免疫逃避分子,称为葡萄球菌超抗原样蛋白 1、5 和 10(SSL1、SSL5 和 SSL10)。这三种 SSL 都抑制了宿主重要的免疫过程,并有助于金黄色葡萄球菌的免疫逃避。本研究旨在从合成抗体噬菌体文库中鉴定单链可变片段(scFv)抗体,这些抗体可以识别这三种 SSL 中的任何一种,并可以阻断 SSL 与其各自的人类靶标的相互作用。在针对 SSL1、SSL5 和 SSL10 进行三轮淘选后,分离出了这些抗体,并使用基于时间分辨荧光的免疫测定法研究了它们与 SSL 的结合能力。我们总共成功获得了 44 个独特的克隆,这些克隆显示出与 SSL1、SSL5 或 SSL10 结合的活性。通过 MMP9 酶活性测定、P-选择素糖蛋白配体 1 竞争性结合测定和 IgG1 介导的吞噬测定,测试了 SSL 识别 scFv 抑制 SSL 功能的能力。我们可以证明,一种 scFv 能够以浓度依赖的方式抑制 SSL1 并维持 MMP9 活性。最后,对这种抑制性 scFv 的结构进行建模,并通过蛋白质-蛋白质对接来创建可能的 scFv-SSL1 复合物模型。对复合物模型进行了 100ns 的分子动力学模拟,以评估抗体的可能结合模式。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/4d4eecf4ce58/MBO3-12-e1371-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/223a034314f9/MBO3-12-e1371-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/184d437e6e97/MBO3-12-e1371-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/a5972c845076/MBO3-12-e1371-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/7e8aa53e904b/MBO3-12-e1371-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/aeb640472d72/MBO3-12-e1371-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/35ff4b3d35f7/MBO3-12-e1371-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/9ed88d78f7fb/MBO3-12-e1371-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/2c8e15014b1a/MBO3-12-e1371-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/f17091fbdb0b/MBO3-12-e1371-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/6a0600d0ba0a/MBO3-12-e1371-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/18e251c13aaa/MBO3-12-e1371-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/52359ebdc563/MBO3-12-e1371-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/f67f7dbe6f8d/MBO3-12-e1371-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/cf51182253d6/MBO3-12-e1371-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/2c04497c9856/MBO3-12-e1371-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/4d4eecf4ce58/MBO3-12-e1371-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/223a034314f9/MBO3-12-e1371-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/184d437e6e97/MBO3-12-e1371-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/a5972c845076/MBO3-12-e1371-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/7e8aa53e904b/MBO3-12-e1371-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/aeb640472d72/MBO3-12-e1371-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/35ff4b3d35f7/MBO3-12-e1371-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/9ed88d78f7fb/MBO3-12-e1371-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/2c8e15014b1a/MBO3-12-e1371-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/f17091fbdb0b/MBO3-12-e1371-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/6a0600d0ba0a/MBO3-12-e1371-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/18e251c13aaa/MBO3-12-e1371-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/52359ebdc563/MBO3-12-e1371-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/f67f7dbe6f8d/MBO3-12-e1371-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/cf51182253d6/MBO3-12-e1371-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/2c04497c9856/MBO3-12-e1371-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbb1/10350561/4d4eecf4ce58/MBO3-12-e1371-g006.jpg

相似文献

1
Isolation and functional analysis of phage-displayed antibody fragments targeting the staphylococcal superantigen-like proteins.分离和功能分析针对葡萄球菌超抗原样蛋白的噬菌体展示抗体片段。
Microbiologyopen. 2023 Aug;12(4):e1371. doi: 10.1002/mbo3.1371.
2
Generation of a Monoclonal Antibody Against Staphylococcal Superantigen-Like Protein 5 (SSL5) That Discriminates SSL5 from Other SSL Proteins.一种针对葡萄球菌超抗原样蛋白5(SSL5)的单克隆抗体的产生,该抗体可将SSL5与其他SSL蛋白区分开来。
Monoclon Antib Immunodiagn Immunother. 2018 Nov;37(5):212-217. doi: 10.1089/mab.2018.0016.
3
Staphylococcal Superantigen-Like Protein 1 and 5 (SSL1 & SSL5) Limit Neutrophil Chemotaxis and Migration through MMP-Inhibition.葡萄球菌超抗原样蛋白1和5(SSL1和SSL5)通过抑制基质金属蛋白酶限制中性粒细胞趋化和迁移。
Int J Mol Sci. 2016 Jul 5;17(7):1072. doi: 10.3390/ijms17071072.
4
Staphylococcal superantigen-like protein 10 (SSL10) inhibits blood coagulation by binding to prothrombin and factor Xa via their γ-carboxyglutamic acid (Gla) domain.葡萄球菌超抗原样蛋白 10(SSL10)通过与凝血酶原和因子 Xa 结合,利用其 γ-羧基谷氨酸(Gla)结构域抑制血液凝固。
J Biol Chem. 2013 Jul 26;288(30):21569-80. doi: 10.1074/jbc.M113.451419. Epub 2013 Jun 10.
5
Role of sialic acid-containing glycans of matrix metalloproteinase-9 (MMP-9) in the interaction between MMP-9 and staphylococcal superantigen-like protein 5.基质金属蛋白酶-9(MMP-9)含唾液酸聚糖在MMP-9与葡萄球菌超抗原样蛋白5相互作用中的作用
Microbiol Immunol. 2018 Mar;62(3):168-175. doi: 10.1111/1348-0421.12573. Epub 2018 Feb 14.
6
Specificity of staphylococcal superantigen-like protein 10 toward the human IgG1 Fc domain.葡萄球菌超抗原样蛋白 10 对人 IgG1 Fc 结构域的特异性。
J Immunol. 2010 Jun 1;184(11):6283-92. doi: 10.4049/jimmunol.0903311. Epub 2010 Apr 28.
7
Staphylococcal superantigen-like protein 10 binds to phosphatidylserine and apoptotic cells.葡萄球菌超抗原样蛋白 10 与磷脂酰丝氨酸和凋亡细胞结合。
Microbiol Immunol. 2012 Jun;56(6):363-71. doi: 10.1111/j.1348-0421.2012.00452.x.
8
Identification of human plasma C1 inhibitor as a target protein for staphylococcal superantigen-like protein 5 (SSL5).鉴定人血浆 C1 抑制剂为葡萄球菌超抗原样蛋白 5(SSL5)的靶蛋白。
Biochem Biophys Res Commun. 2019 Jan 22;508(4):1162-1167. doi: 10.1016/j.bbrc.2018.12.026. Epub 2018 Dec 13.
9
Staphylococcal superantigen-like proteins interact with human MAP kinase signaling protein ERK2.葡萄球菌超抗原样蛋白与人 MAP 激酶信号蛋白 ERK2 相互作用。
FEBS Lett. 2020 Jan;594(2):266-277. doi: 10.1002/1873-3468.13590. Epub 2019 Sep 11.
10
Staphylococcal superantigen-like protein 5 inhibits matrix metalloproteinase 9 from human neutrophils.葡萄球菌超抗原样蛋白 5 抑制人中性粒细胞基质金属蛋白酶 9。
Infect Immun. 2010 Jul;78(7):3298-305. doi: 10.1128/IAI.00178-10. Epub 2010 May 17.

引用本文的文献

1
SSL5-AnxA5 Fusion Protein Constructed Based on Human Atherosclerotic Plaque scRNA-Seq Data Preventing the Binding of Apoptotic Endothelial Cells, Platelets, and Inflammatory Cells.基于人类动脉粥样硬化斑块单细胞RNA测序数据构建的SSL5-AnxA5融合蛋白可阻止凋亡内皮细胞、血小板和炎症细胞的结合。
Biomedicines. 2024 Dec 24;13(1):8. doi: 10.3390/biomedicines13010008.

本文引用的文献

1
Phage Display-Derived Peptides and Antibodies for Bacterial Infectious Diseases Therapy and Diagnosis.噬菌体展示技术衍生的肽和抗体在细菌性传染病治疗和诊断中的应用。
Molecules. 2023 Mar 14;28(6):2621. doi: 10.3390/molecules28062621.
2
Anti-virulence therapeutic strategies against bacterial infections: recent advances.针对细菌感染的抗毒力治疗策略:最新进展
Germs. 2022 Jun 30;12(2):262-275. doi: 10.18683/germs.2022.1328. eCollection 2022 Jun.
3
A novel fully human recombinant antibody neutralizing α-hemolysin of Staphylococcus aureus.
一种新型的、完全人源化的抗金黄色葡萄球菌α-溶血素的重组抗体。
APMIS. 2022 Sep;130(9):578-589. doi: 10.1111/apm.13258. Epub 2022 Jul 12.
4
Multiple Domains of Staphylococcal Superantigen-like Protein 11 (SSL11) Contribute to Neutrophil Inhibition.葡萄球菌超抗原样蛋白 11(SSL11)的多个结构域有助于中性粒细胞的抑制。
Biochemistry. 2022 Apr 5;61(7):616-624. doi: 10.1021/acs.biochem.2c00018. Epub 2022 Mar 14.
5
Mechanistic Insights into SARS-CoV-2 Main Protease Inhibition Reveals Hotspot Residues.SARS-CoV-2 主要蛋白酶抑制的机制研究揭示了热点残基。
J Chem Inf Model. 2021 Dec 27;61(12):6053-6065. doi: 10.1021/acs.jcim.1c00928. Epub 2021 Nov 29.
6
The Case against Antibiotics and for Anti-Virulence Therapeutics.反对使用抗生素而支持抗毒力疗法的理由。
Microorganisms. 2021 Sep 28;9(10):2049. doi: 10.3390/microorganisms9102049.
7
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素:一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
8
Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization.对抗IgE药物奥马珠单抗的Fab片段进行工程改造,以防止Fab结晶并使IgE-Fc复合物结晶。
Acta Crystallogr F Struct Biol Commun. 2020 Mar 1;76(Pt 3):116-129. doi: 10.1107/S2053230X20001466. Epub 2020 Mar 2.
9
The global preclinical antibacterial pipeline.全球临床前抗菌药物研发管线。
Nat Rev Microbiol. 2020 May;18(5):275-285. doi: 10.1038/s41579-019-0288-0. Epub 2019 Nov 19.
10
David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments.大卫与歌利亚之战:抗体片段的结构、功能及临床前景
Antibodies (Basel). 2019 Apr 9;8(2):28. doi: 10.3390/antib8020028.